Clinical trials
Observational Vision Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
95 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2006 | 1 |
| 2008 | 2 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 7 |
| 2017 | 7 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 8 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 10 |
| 2025 | 11 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 50 |
| Unknown status | 14 |
| Recruiting | 13 |
| Not yet recruiting | 8 |
| Withdrawn | 4 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Democritus University of Thrace | 3 |
| Amore Filippo | 2 |
| Bayer | 2 |
| Fondation Ophtalmologique Adolphe de Rothschild | 2 |
| Medical University of Lublin | 2 |
| National Eye Institute (NEI) | 2 |
| Shanghai Eye Disease Prevention and Treatment Center | 2 |
| Sun Yat-sen University | 2 |
| University Hospital, Strasbourg, France | 2 |
| University of Rochester | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vision Disorders | 95 |
| Blindness | 13 |
| Macular Degeneration | 8 |
| Eye Diseases | 7 |
| Cataract | 6 |
| Refractive Errors | 6 |
| Diabetic Retinopathy | 4 |
| Hearing Loss | 4 |
| Hypertension | 4 |
| Retinal Diseases | 4 |
Trials
Showing 76 to 95 of 95. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.